Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Davison Beth A, Abbate Antonio, Cotter Gad, Pascual-Figal Domingo, Van Tassell Benjamin, Villota Julio Núñez, Atabaeva Lina, Freund Yonathan, Aimo Alberto, Biegus Jan, Golino Michele, Del Buono Marco Giuseppe, Chioncel Ovidiu, Cohen-Solal Alain, Edwards Christopher, Fernández-Villa Noelia, Filippatos Gerasimos, González-Juanatey José Ramón, Hayrapetyan Hamlet, Ibáñez Borja, Iborra Pau Llàcer, Moroni Francesco, Ter Maaten Jozine M, Markley Roshanak, González-Martín Javier, Martínez-Sellés Manuel, Drambyan Mayranush, Metra Marco, Mirabet Sonia, Mshetsyan Andranik, Novosadova Maria, Pagnesi Matteo, Ponikowski Piotr, Riquelme-Pérez Alejandro, Sadoune Malha, Sánchez Manuel Anguita, Simon Tabassome, Taibo-Urquía Mikel, Takagi Koji, Villar Sandra, Liu Chao, Voors Adriaan A, Mebazaa Alexandre, Mann Douglas L, Bayés-Genís Antoni
Аннотация
We examined current evidence regarding the effects of anti-inflammatory therapies in patients with acute heart failure (AHF) on the risk of cardiovascular outcomes, inflammatory markers, natriuretic peptides, and renal function. Despite growing evidence that inflammation plays a pivotal role in both the development and progression of heart failure, including AHF, only a few trials have been conducted to date in patients with AHF. A systematic literature search of PubMed, Medline, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov was conducted in November 2024 to identify randomized controlled trials (RCTs) evaluating anti-inflammatory therapies in adult patients with AHF. Meta-analyses were conducted to estimate effects on clinical outcomes (death, HF readmission, or worsening HF) and inflammatory and other markers. Five RCTs were identified that enrolled a total of 289 patients to an anti-inflammatory intervention and 273 to a control. Prednisone was examined in two RCTs, anakinra in two, and colchicine in one. Three of the five trials required elevated C-reactive protein (CRP) level for entry. Anti-inflammatory therapy was associated with a reduced risk of the composite outcome (hazard ratio 0.55 [95% CI 0.35-0.86]) and an overall 54% greater reduction in CRP to end of therapy (ratio of geometric mean ratios 0.46 [95% CI 0.29-0.73]), which varied across studies. NT-proBNP and creatinine were not significantly affected. The analysis is limited by the small number of studies but suggests that anti-inflammatory therapy reduces inflammation and may reduce the risk of adverse clinical outcomes in patients with AHF.